EmpowHER-303: what clinicians are saying
zanidatamab in metastatic HER2-positive breast cancer · NCT06435429 ↗ · Phase 3 · Jazz Pharmaceuticals
A physician described in the sources as presenting EmpowHER-303 sees treatment after T-DXd as unsettled, while identifying chemotherapy plus trastuzumab as a usual option. Their rationale for studying zanidatamab rests on earlier combination activity, which does not establish benefit in this setting. The sources reviewed for this edition contain no trial outcome data to judge added benefit or tolerability.
Created with AI · how we check it
- edition 1
- commentary checked Nov 19, 2026
- 49 verified statements
This edition $750, with MCP access for your AI agent. Get this report
7 findings, and what sits behind each
01. Post-T-DXd treatment: why speakers look to EmpowHER-303 for answers
2 of the report's 3 cited clinicians · 8 statements from 3 speakers in 4 sources, 2 of them podcasts or videos · 5 passages
Limitations recorded: 2.
Draws on: Population and setting, The comparison, Safety and tolerability, Design and conduct.
02. EmpowHER-303: what speakers say
1 of the report's 3 cited clinicians · 4 statements from 1 speaker in 3 sources, 2 of them podcasts or videos · 3 passages
Limitations recorded: 2.
Draws on: The comparison, Population and setting, Safety and tolerability, Design and conduct.
03. Zanidatamab: why a clinician links dual-site HER2 binding to possible benefit
1 of the report's 3 cited clinicians · 6 statements from 1 speaker in 2 sources, all podcasts or videos · 3 passages
Limitations recorded: 2.
Draws on: The comparison.
04. EmpowHER-303 participation: why a clinician advises discussion and eligibility support
1 of the report's 3 cited clinicians · 8 statements from 1 speaker in 3 sources, all podcasts or videos · 4 passages
Limitations recorded: 4.
Draws on: Design and conduct, Population and setting, The comparison, Safety and tolerability.
05. Trials: a clinician advises more talks; a speaker welcomes expected Brazil entry
1 of the report's 3 cited clinicians · 9 statements from 2 speakers in 4 sources, 3 of them podcasts or videos · 7 passages
Limitations recorded: 2.
Draws on: Design and conduct.
Beyond the trial population
06. Earlier zanidatamab data: what speakers highlight in antitumor activity
1 of the report's 3 cited clinicians · 8 statements from 4 speakers in 5 sources, 1 of them a podcast or video · 5 passages
Limitations recorded: 4.
07. HER2+ care: why a speaker weighs timing, resistance and lasting toxicity
No named clinician · accounts and unnamed speakers · 4 statements from 1 speaker in 1 source, a podcast or video · 1 passage
Limitations recorded: 3.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 7
2 of the report's 3 cited clinicians
Post-T-DXd treatment: why speakers look to EmpowHER-303 for answers
8 statements from 3 speakers in 4 sources, 2 of them podcasts or videos
3 of the 3 named speakers in this finding hold this view
- 8
- statements
- 5
- passages
- 4
- sources
- 3
- speakers
What the statements areViews 3Questions and uncertainty 2Clinical experience 1Comparisons 0Restated results and context 2Statement-to-passage links (a passage can back several statements)Supporting a statement 9Giving context 0Recorded with the findingLimitations: 2
2 posts and articles · 2 podcasts and video
Draws on: Population and setting, The comparison, Safety and tolerability, Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
2 of the 7 findings and 10 of the 49 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (8)
BICR, blinded independent central review; HCP, healthcare professional; HER2, human epidermal growth factor receptor 2; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; T-DXd, trastuzumab deruxtecan.
The full EmpowHER-303 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 18commentary sources screened
- 10sources cited by verified statements
- 8named in screened sources
- 8speakers cited in the report
- 8cited speakers with a verified identity
3 cited clinicians, speakers with a confirmed clinical role, of them 3 physicians. By role and specialty:
- 2 physician, Medical oncology
- 1 physician, specialty not confirmed
Also in the sources: 1 organizational or shared account, not counted as people.
- 49verified statements, each linked to its source
- 28of them from speakers with a confirmed clinical role
- 7findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 49 | Paid |
| Who said each statement: the cited speakers | 8 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 8 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 10 | Free |
| Sources with links | 10 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
10 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR) | 3 | 3 |
| Secondary endpoints | 3 | 3 |
| Population and setting | 11 | 5 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 9 | 3 |
| Safety and tolerability | 9 | 6 |
| Design and conduct | 6 | 2 |
| Proposed biological rationale for zanidatamab after T-DXd | 5 | 2 |
| Earlier zanidatamab evidence in advanced or pretreated breast cancer | 10 | 6 |
| Trial access, referral and reasons to consider participation | 9 | 4 |
| Sequencing, resistance and patient priorities across treatment | 5 | 2 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
49 verified statements from 10 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 36 statements · 74% | ||||
| YouTube | 36 | 3 | 3 | |
| Posts · 11 statements · 22% | ||||
| X threads | 11 | 6 | 13 | |
| Bluesky threads | 0 | 0 | 2 | |
| Primary sources · 2 statements · 4%cited for context, not screened | ||||
| Registry | 2 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 12 / quarter
- Screened window
- Dec 3, 2024 → Oct 16, 2026
- Cited window
- Dec 13, 2024 → Oct 16, 2026
- Retrieved
- Nov 19, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment
- Registry
- NCT06435429
- Study IDs
- JZP598-303 · 2023-508960-31-00 (EU CTR)
- Sponsor
- Jazz Pharmaceuticals
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 550 estimated
- Registered
- 2024-05-30
- Start
- 2024-08-13 actual
- Primary completion
- 2028-04-28 estimated
- Primary endpoint
- Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)
- Interventions
- 6 registered
More on: Breast cancer, zanidatamab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 21 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 32 sources about other trials or topics are not included.
- The sources reviewed do not include an EmpowHER-303 outcome dataset. Earlier-phase activity, mechanistic expectations and participation counseling cannot establish comparative efficacy or safety in its post-T-DXd population.
- No separate protocol or exact-trial results publication was identified for this edition. The complete eligibility criteria therefore cannot be reconciled from these discussions alone.
Show all 11 known gaps +Fewer −
- Searches emphasized explicit trial names and identifiers and may miss unnamed references or differently transcribed discussion. Absence of a criticism here does not establish that no such criticism exists.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- A speaker is described in the sources as presenting EmpowHER-303. Their views should not be counted as an independent external endorsement of the study.
- A YouTube channel publisher describes an AI-generated avatar. Its narration has no proven individual speaker and includes a control-treatment description that conflicts with the registry.
- Reposts are not additional independent clinical opinions. Neither source counts nor favorable comments establish consensus.
- The sources reviewed do not establish a complete current regulatory picture across indications and countries; the video's approval wording remains a dated source statement.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 19, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. EmpowHER-303 (NCT06435429): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/empowher-303-nct06435429
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "EmpowHER-303" (NCT06435429), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "empowher-303-nct06435429". If you cannot make requests, read https://www.erudio.com/reports/empowher-303-nct06435429.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06435429", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06435429 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/empowher-303-nct06435429.json
curl https://www.erudio.com/reports/empowher-303-nct06435429.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "empowher-303-nct06435429" })release 4d062849615bbfa1373c947708df575e89b62641d712882733775298276fc6b4
Questions
How much does the EmpowHER-303 report cost?
One edition costs $750 (Focused · 49 verified statements · 28 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the EmpowHER-303 report cover?
49 statements from 10 sources (3 videos, 6 posts, 1 registry record), 28 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the EmpowHER-303 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "empowher-303-nct06435429" }) previews it and create_order({ "report": "empowher-303-nct06435429", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the EmpowHER-303 report?
Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.